Time to achieve remission determines time to be in remission

Por Schipper, Lydia G, Fransen, Jaap, den Broeder, Alfons A, Van Riel, Piet LCM
Publicado em 2010

Acute and probable chronic Q fever during anti-TNFα and anti B-cell immunotherapy: a case report

Por Schoffelen, Teske, den Broeder, Alfons A, Nabuurs-Franssen, Marrigje, van Deuren, Marcel, Sprong, Tom
Publicado em 2014

The Dutch Lower Extremity Functional Scale was highly reliable, valid and responsive in individuals with hip/knee osteoarthritis: a validation study

Por Hoogeboom, Thomas J, de Bie, Rob A, den Broeder, Alfons A, van den Ende, Cornelia HM
Publicado em 2012

Longitudinal impact of joint pain comorbidity on quality of life and activity levels in knee osteoarthritis: data from the Osteoarthritis Initiative

Por Hoogeboom, Thomas J., den Broeder, Alfons A., de Bie, Rob A., van den Ende, Cornelia H. M.
Publicado em 2013

Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis

Por Zwikker, Hanneke E, van Dulmen, Sandra, den Broeder, Alfons A, van den Bemt, Bart J, van den Ende, Cornelia H
Publicado no Patient Prefer Adherence (2014)

Non-pharmacological care for patients with generalized osteoarthritis: design of a randomized clinical trial

Por Hoogeboom, Thomas J, Stukstette, Mirelle JPM, de Bie, Rob A, Cornelissen, Jessica, den Broeder, Alfons A, van den Ende, Cornelia HM
Publicado em 2010

Feasibility and potential effectiveness of a non-pharmacological multidisciplinary care programme for persons with generalised osteoarthritis: a randomised, multiple-baseline singl...

Por Hoogeboom, Thomas J, Kwakkenbos, Linda, Rietveld, Leonie, den Broeder, Alfons A, de Bie, Rob A, van den Ende, Cornelia H M
Publicado em 2012

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an o...

Por van der Maas, Aatke, van den Bemt, Bart JF, Wolbink, Gertjan, van den Hoogen, Frank HJ, van Riel, Piet LCM, den Broeder, Alfons A
Publicado em 2012

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

Por van den Bemt, Bart JF, den Broeder, Alfons A, Wolbink, GJ, Hekster, Yechiel A, van Riel, Piet LCM, Benraad, Bart, van den Hoogen, Frank HJ
Publicado em 2011

Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review

Por Tweehuysen, Lieke, van den Ende, Cornelia H., Beeren, Fenna M. M., Been, Evelien M. J., van den Hoogen, Frank H. J., den Broeder, Alfons A.
Publicado no Arthritis Rheumatol (2017)

What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?

Por Bouman, Chantal A M, den Broeder, Alfons A, van der Maas, Aatke, van den Hoogen, Frank H J, Landewé, Robert B M, van Herwaarden, Noortje
Publicado no RMD Open (2017)

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study

Por den Broeder, Alfons A, van Herwaarden, Noortje, van der Maas, Aatke, van den Hoogen, Frank HJ, Bijlsma, Johannes W, van Vollenhoven, Ronald F, van den Bemt, Bart JF
Publicado em 2013

Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry

Por Vermeer, Marloes, Kievit, Wietske, Kuper, Hillechiena H, Braakman-Jansen, Louise MA, Bernelot Moens, Hein J, Zijlstra, Theo R, den Broeder, Alfons A, van Riel, Piet LCM, Fransen, Jaap, van de Laar, Mart AFJ
Publicado em 2013

The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis

Por van den Bemt, Bart J F, den Broeder, Alfons A, Wolbink, Gert-Jan, van den Maas, Aatke, Hekster, Yechiel A, van Riel, Piet L C M, Benraad, H Bart, van den Hoogen, Frank H J
Publicado em 2013

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiori...

Por van Herwaarden, Noortje, van der Maas, Aatke, Minten, Michiel J M, van den Hoogen, Frank H J, Kievit, Wietske, van Vollenhoven, Ronald F, Bijlsma, Johannes W J, van den Bemt, Bart J F, den Broeder, Alfons A
Publicado no BMJ (2015)

Validation Study of Existing Gene Expression Signatures for Anti-TNF Treatment in Patients with Rheumatoid Arthritis

Por Toonen, Erik J. M., Gilissen, Christian, Franke, Barbara, Kievit, Wietske, Eijsbouts, Agnes M., den Broeder, Alfons A., van Reijmersdal, Simon V., Veltman, Joris A., Scheffer, Hans, Radstake, Timothy R. D. J., van Riel, Piet L. C. M., Barrera, Pilar, Coenen, Marieke J. H.
Publicado em 2012